clinical qsp model clinical abm software matlab (MathWorks Inc)
Structured Review
![FIGURE 2 | Schematic diagram of human <t>QSP</t> model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.](https://pub-med-unpaywalled-images-cdn.bioz.com/pub_med_ids_ending_with_6360/pm39776360/pm39776360__page4_image1.jpg)
Clinical Qsp Model Clinical Abm Software Matlab, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 97/100, based on 545 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clinical qsp model clinical abm software matlab/product/MathWorks Inc
Average 97 stars, based on 545 article reviews
Images
1) Product Images from "A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab."
Article Title: A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.
Journal: CPT: pharmacometrics & systems pharmacology
doi: 10.1002/psp4.13297
Figure Legend Snippet: FIGURE 2 | Schematic diagram of human QSP model. Human QSP model was built by combining the reported model of Wang et al. [33] and a por- tion of oncolytic virus mechanism of action in the preclinical QSP model shown in Figure 1. APC, antigen-presenting cell; Arg-1, arginase 1; aTCD8, activated CD8-positive T cells; CCL-2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; e, rate of tumor-cell kill by differentiated effector T cells; IL-2, interleukin 2; IL-7, interleukin 7; IL-12, interleukin 12; mAPC, MHC-presenting APC; MDSC, myeloid- derived suppressor cells; MHC, major histocompatibility complex; nTCD4, naïve CD4-positive T cells; nTCD8, naïve CD8-positive T cells; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; QSP, quantitative systems pharmacology; TCR, T-cell receptor; Teff, effector T cells; Treg, regulatory T cells; Tumi, infected tumor cells; Tumni, noninfected tumor cells; Valpha, viral production size.
Techniques Used: Virus, Derivative Assay, Immunopeptidomics, Infection